CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 8, 2017

Primary Completion Date

September 8, 2038

Study Completion Date

December 8, 2038

Conditions

Prostate Cancer

Interventions

BIOLOGICAL

CART-PSMA-TGFβRDN cells

autologous CAR T cells

DRUG

Cyclophosphamide

300 mg/m2/day given over 3 days

DRUG

Fludarabine

30 mg/m2/day given over 3 days

Trial Locations (1)

University of Pennsylvania, Philadelphia

All Listed Sponsors

lead

University of Pennsylvania

OTHER